Sugi Predict

Sugi Predict / Compounds / SCHEMBL363249

SCHEMBL363249

SCHEMBL363249

CCOC(=O)c1ccnc(C)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JMJD6 Q6NYC1 4/20 0.58
▸ PIK3CA P42336 1/20 0.56
▸ CA12 O43570 3/20 0.54
▸ CA1 P00915 3/20 0.54
▸ CA2 P00918 3/20 0.54
▸ CA7 P43166 3/20 0.54
▸ CA9 Q16790 3/20 0.54
▸ CA14 Q9ULX7 3/20 0.54
▸ ESR1 P03372 1/20 0.50
▸ ESR2 Q92731 1/20 0.50
▸ HSD17B2 P37059 1/20 0.49
▸ LMNA P02545 1/20 0.49
▸ CYP1A2 P05177 1/20 0.49
▸ CYP3A4 P08684 1/20 0.49
▸ MAOA P21397 1/20 0.49
▸ KDM5A P29375 1/20 0.48
▸ KDM5C P41229 1/20 0.48
▸ KDM4C Q9H3R0 1/20 0.48
▸ KDM5B Q9UGL1 1/20 0.48
▸ RAB9A P51151 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28990167 0.94 CYP2C9 (0.54) JMJD6PIK3CACA12CA1CA2
SCHEMBL811785 0.86 JMJD6 (0.76) JMJD6PIK3CACA12CA1CA2
SCHEMBL30171421 0.86 JMJD6 (0.76) JMJD6PIK3CACA12CA1CA2
SCHEMBL6500351 0.84 JMJD6 (0.57) JMJD6PIK3CACA12CA1CA2
SCHEMBL29466587 0.84 JMJD6 (0.57) JMJD6PIK3CACA12CA1CA2
SCHEMBL930636 0.84 JMJD6 (0.57) JMJD6PIK3CACA12CA1CA2
SCHEMBL14825305 0.83 JMJD6 (0.53) JMJD6PIK3CACA12CA1CA2
SCHEMBL3727609 0.83 JMJD6 (0.56) JMJD6PIK3CACA12CA1CA2
SCHEMBL256755 0.83 GABRP (0.56) JMJD6PIK3CACA12CA1CA2
SCHEMBL3723629 0.83 JMJD6 (0.56) JMJD6PIK3CACA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240217964-A1 QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS NEWAVE PHARMACEUTICAL INC. 2024-07-04 — — US disclosed
CN-116034107-A Quinuclidinone analogs as anticancer agents 新波制药有限公司 2023-04-28 — — CN disclosed
US-20230089530-A1 QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS NEWAVE PHARMACEUTICAL INC. 2023-03-23 — — US disclosed
EP-4100407-A1 QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS Newave Pharmaceutical Inc. (US) 2022-12-14 — — EP disclosed
WO-2022204109-A1 QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS NEWAVE PHARMACEUTICAL INC. (US) 2022-09-29 — — WO disclosed
WO-2021158948-A1 QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS NEWAVE PHARMACEUTICAL INC. (US) 2021-08-12 — — WO disclosed
US-10709712-B2 Biaryl amide compounds as kinase inhibitors NOVARTIS AG (CH) 2020-07-14 — — US disclosed
US-20190175606-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2019-06-13 — — US disclosed
EP-2861597-B1 SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS DOMAIN THERAPEUTICS (FR) 2017-09-06 — — EP disclosed
US-20170010272-A1 RAPID PHENOTYPE TESTS FOR ANTITUBERCULAR DRUG SENSITIVITY AND RESISTANCE TRIAD NATIONAL SECURITY, LLC 2017-01-12 — — US disclosed
US-20030073704-A1 Substituted pyridone compounds and methods of use AMGEN INC. 2003-04-17 — — US disclosed
US-20030069425-A1 Substituted pyrimidine compounds and methods of use AMGEN INC. 2003-04-10 — — US disclosed
US-6420385-B1 INFLAMMATORY, PAIN AND DIABETES DISEASES, AMGEN INC. 2002-07-16 — — US disclosed
US-6410729-B1 ANALGESICS; ANTIDIABETIC AGENTS; ANTIINFLAMMATORY AGENTS AMGEN INC. 2002-06-25 — — US disclosed
US-6096753-A Substituted pyrimidinone and pyridone compounds and methods of use AMGEN INC. (US) 2000-08-01 — — US disclosed
EP-0948496-A2 SUBSTITUTED PYRIMIDINONE AND PYRIDONE COMPOUNDS AND METHODS OF USE Amgen inc. (US) 1999-10-13 — — EP disclosed
EP-0948497-A2 SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE Amgen inc. (US) 1999-10-13 — — EP disclosed
WO-1998024780-A2 SUBSTITUTED PYRIMIDINONE AND PYRIDINONE COMPOUNDS AND THEIR USE AMGEN INC. (US) 1998-06-11 — — WO disclosed
WO-1998024782-A2 SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AMGEN INC. (US) 1998-06-11 — — WO disclosed
US-5223510-A ALKYLAMINOALKYL DERIVATIVES OF BENZOFURAN, BENZOTHIOPHENE, INDOLE AND INDOLIZINE, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM SANOFI (FR) 1993-06-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230089530-A1 QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS NQO2, CNKSR1, NQO1 JMJD6 550/4885PIK3CA 1159/4885CA12 2567/4885
US-20240217964-A1 QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS NQO2, PRMT1, PRMT7 JMJD6 288/4885PIK3CA 1292/4885CA12 3906/4885
US-20030069425-A1 Substituted pyrimidine compounds and methods of use DPYD, IL6, IL1B JMJD6 2296/4885PIK3CA 441/4885CA12 4823/4885
US-10709712-B2 Biaryl amide compounds as kinase inhibitors BRAF, RAF1, NRAS JMJD6 937/4885PIK3CA 44/4885CA12 4577/4885
US-20190175606-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS BRAF, RAF1, NRAS JMJD6 937/4885PIK3CA 44/4885CA12 4577/4885
US-20030073704-A1 Substituted pyridone compounds and methods of use IL6, IL1B, IL1A JMJD6 1312/4885PIK3CA 488/4885CA12 4882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.